JPRN-UMIN000002042已完成2 期
Phase II trial of mFOLFOX6/XELOX plus bevacizumab with oxaliplatin in a stop and go fashion in advanced metastatic colorectal cancer - J-M-CONcePT trial phase II study(T-CORE0901)
Tohoku Clinical oncology, reserach and Education Society (T-CORE)0 个研究点目标入组 65 人开始时间: 2009年6月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. patient treated with blood transfusion, blood products or G-CSF within 7 days before registration. 2.patient who has or clinically suspicious for brain metastasis. 3. patient with a mental disorder or a history of a CNS disorder 4. patient with paresthesia 5. patient who need drainage of peritoneal, pleural or pericardial effusion. 6. double cancer 7. hypercalcemia (albumin-modified Ca value 12mg/dl or more). 8. poorly controlled diabetes mellitus. 9. proteinuria (grade 2 or more) 10. history of severe drug hypersensitivity or drug allergy 11. poorly controlled hypertension 12. obvious abnormality in ECG
研究者
相似试验
进行中（未招募）
不适用
Phase II trial FOLFOX combined with Bevacizumab, Cetuximab and Imatinib in patients with advanced untreated colorectal cancer - NDEUCTR2006-001779-39-ITAzienda Ospedaliera Universitaria S.Martino - U.O. Oncologia Medica - Genova
招募中
2 期
Phase II trial of Bevacizumab with XELOX as an adjuvant treatment after resection of colorectal liver metastasesColorectal liver metastasesJPRN-UMIN000004352Tohoku University Graduate School of Medicine Division of Integrated Surgery and Oncology45
招募中
2 期
Phase II trial of XELOX plus bevacizumab for metastatic colorectal cancer.advanced colorectal cancerJPRN-UMIN000006397agoya Surgical Oncology Group50
进行中（未招募）
不适用
Marker Evaluation for Avastin Research in colorectal cancerEUCTR2011-004755-39-EEGenentech, Inc.360
进行中（未招募）
1 期
Marker Evaluation for Avastin Research in colorectal cancerMetastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2011-004755-39-IEGenentech, Inc.360